Virax Biolabs Seeks Market Rebound After Nasdaq Compliance Win
Virax Biolabs CEO James Foster is pushing to close the gap between the company’s market valuation and its underlying assets, following a fiscal year marked by a 1-for-25 share consolidation, a successful Nasdaq compliance recovery, and a new commercial supply agreement covering six Southeast Asian markets.
The biotechnology firm, which specializes in T cell immune profiling, reported $6.4 million in cash and $7.3 million in shareholders' equity as of March 31, 2026. Despite these figures, the company’s public market valuation has lagged behind its audited balance sheet. To bolster its financial footing, Virax generated roughly $3.3 million in gross proceeds through the exercise of preferred investment options in July. This liquidity injection is intended to support the ongoing development of the ViraxImmune platform and the commercial rollout of its ImmuneSelect product line.
Management is now shifting focus toward operational execution. The recent agreement with Fosun Diagnostics targets regional expansion in Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. While the company has successfully reduced its net loss—down to $5.0 million from $6.1 million in fiscal 2025—Foster emphasized that the primary objective remains translating these commercial milestones into consistent revenue. Having regained compliance with Nasdaq’s minimum bid price requirement, the company is prioritizing clinical validation and U.S. market-entry strategies to justify its valuation to shareholders.
Comments (0)
No comments yet. Be the first!